Ionis Pharmaceuticals
IONS
396 hedge funds and large institutions have $8.14B invested in Ionis Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 67 funds opening new positions, 167 increasing their positions, 95 reducing their positions, and 56 closing their positions.
76% more repeat investments, than reductions
Existing positions increased: 167 | Existing positions reduced: 95
20% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 56
5.36% more ownership
Funds ownership: 84.87% → 90.24% (+5.4%)
1% more funds holding
Funds holding: 392 → 396 (+4)
15% less capital invested
Capital invested by funds: $9.53B → $8.14B (-$1.39B)
32% less call options, than puts
Call options by funds: $81.3M | Put options by funds: $119M
40% less funds holding in top 10
Funds holding in top 10: 10 → 6 (-4)
Top Buyers
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$541M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$155M |
| 3 |
Renaissance Technologies
New York
|
+$124M |
| 4 |
BlackRock
New York
|
+$83.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$73M |
Top Sellers
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$63.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$34.1M |
| 3 |
PP
PDT Partners
New York
|
-$27.7M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$20.1M |
| 5 |
SI
Scout Investments
Kansas City,
Missouri
|
-$15.3M |
IONS Hedge Fund Activity: Q2 2019 in Review
396 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q2 2019, worth a combined $8.14B — down 15% from $9.53B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new IONS positions and 56 closed out — a net gain of 11 holders — while 167 added to existing stakes and 95 trimmed.
The largest buyer was Bellevue Group, adding an estimated $541M. The largest seller was First Trust Advisors, cutting an estimated $63.9M.
- 396 institutional investors held Ionis Pharmaceuticals (IONS) as of Q2 2019, up from 392 in Q1 2019.
- Funds reported $8.14B of Ionis Pharmaceuticals stock for Q2 2019, down 15% quarter-over-quarter.
- 67 funds opened new Ionis Pharmaceuticals positions in Q2 2019 and 56 closed out, a net change of +11 holders.
- The largest Ionis Pharmaceuticals buyer in Q2 2019 was Bellevue Group, an estimated $541M added.
- The largest Ionis Pharmaceuticals seller in Q2 2019 was First Trust Advisors, an estimated $63.9M sold.
Based on aggregated 13F filings for Q2 2019.